VJHemOnc is committed to improving our service to you

iwCLL 2019 | Comparing CLL regimens with MRD

VJHemOnc is committed to improving our service to you

John Seymour

John Seymour, MBBS, PhD, Peter MacCallum Cancer Center, Melbourne, Australia, elaborates on the use of measurable residual disease (MRD) to compare the efficacy of chronic lymphocytic leukemia (CLL) treatment regimens. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter